Clinical Manifestations and Treatment of Drug-induced Hepatotoxicity

被引:18
作者
Giordano, Christin M. [1 ]
Zervos, Xaralambos B. [2 ]
机构
[1] Univ Cent Florida, Coll Med, Orlando, FL 32827 USA
[2] Cleveland Clin Florida, Ctr Digest Dis, Dept Gastroenterol, Weston, FL 33331 USA
关键词
Drug-induced liver injury; Drug-induced cholestasis; Drug-induced hepatocellular injury; Management of drug-induced liver injury; INDUCED LIVER-INJURY; LYMPHOCYTE-TRANSFORMATION TEST; CAUSALITY ASSESSMENT; DIAGNOSTIC SCALE; ACETYLCYSTEINE; DISORDERS; OUTCOMES;
D O I
10.1016/j.cld.2013.07.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
With an increase of prescription medication and herbal supplement use, drug-induced liver injury (DILI) has become an increasingly important entity. Because DILI is a usually readily treatable condition, it is essential for providers to reach a diagnosis in a timely fashion. Unfortunately, varied clinical presentations, difficulties in establishing causality, and lack of a gold standard diagnostic criterion may make early diagnosis difficult. This article seeks to define commonly used terminology, describe common clinical presentations of DILI, provide an overview of current diagnostic criteria, and provide management guidelines.
引用
收藏
页码:565 / +
页数:10
相关论文
共 44 条
[1]
Case Definition and Phenotype Standardization in Drug-Induced Liver Injury [J].
Aithal, G. P. ;
Watkins, P. B. ;
Andrade, R. J. ;
Larrey, D. ;
Molokhia, M. ;
Takikawa, H. ;
Hunt, C. M. ;
Wilke, R. A. ;
Avigan, M. ;
Kaplowitz, N. ;
Bjornsson, E. ;
Daly, A. K. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) :806-815
[2]
Drug-induced liver injury:: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period [J].
Andrade, RJ ;
Lucena, MI ;
Fernández, MC ;
Pelaez, G ;
Pachkoria, K ;
García-Ruiz, E ;
García-Munoz, B ;
González-Grande, R ;
Pizarro, A ;
Durán, JA ;
Jiménez, M ;
Rodrigo, L ;
Romero-Gomez, M ;
Navarro, JM ;
Planas, R ;
Costa, J ;
Borras, A ;
Soler, A ;
Salmerón, J ;
Martin-Vivaldi, R .
GASTROENTEROLOGY, 2005, 129 (02) :512-521
[3]
When and how to evaluate mildly elevated liver enzymes in apparently healthy patients [J].
Aragon, George ;
Younossi, Zobair M. .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2010, 77 (03) :195-204
[4]
Epidemiology of Idiosyncratic Drug-Induced Liver Injury [J].
Bell, Lauren N. ;
Chalasani, Naga .
SEMINARS IN LIVER DISEASE, 2009, 29 (04) :337-347
[5]
BENICHOU C, 1990, J HEPATOL, V11, P272
[6]
EASL Clinical Practice Guidelines: Management of cholestatic liver diseases [J].
Beuers, Ulrich ;
Boberg, Kirsten M. ;
Chapman, Roger W. ;
Chazouilleres, Olivier ;
Invernizzi, Pietro ;
Jones, David E. J. ;
Lammert, Frank ;
Pares, Albert ;
Trauner, Michael .
JOURNAL OF HEPATOLOGY, 2009, 51 (02) :237-267
[7]
Long-term follow-up of patients with mild to moderate drug-induced liver injury [J].
Bjornsson, E. ;
Kalaitzakis, E. ;
Klinteberg, V. A. V. ;
Alem, N. ;
Olsson, R. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (01) :79-85
[8]
Outcome and prognostic markers in severe drug-induced liver disease [J].
Björnsson, E ;
Olsson, R .
HEPATOLOGY, 2005, 42 (02) :481-489
[9]
Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-induced Liver Injury in the United States [J].
Chalasani, Naga ;
Fontana, Robert J. ;
Bonkovsky, Herbert L. ;
Watkins, Paul B. ;
Davern, Timothy ;
Serrano, Jose ;
Yang, Hongqiu ;
Rochon, James .
GASTROENTEROLOGY, 2008, 135 (06) :1924-1934
[10]
Review article: drug hepatotoxicity [J].
Chang, C. Y. ;
Schiano, T. D. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (10) :1135-1151